Abstract

BackgroundIncreasingly Burden of Disease (BOD) measures are being used to influence policy decisions because they summarise health loss in an equitable manner. An important part of producing non-fatal BOD estimates are severity distributions (SDs). The Global Burden of Disease (GBD) study use the same SDs across countries due to a lack of available data.
 Aim To develop and assess the impact of national SDs compared with GBD worldwide severity distributions for 21 cancer types.
 MethodsPatient-level records from the Scottish Cancer Registry for 21 cancers were obtained and linked to death registrations. We estimated prevalent cancer cases for 2016 and assigned each case to one of four phases (diagnosis and treatment; controlled; metastatic; and terminal) using GBD 2016 study definitions. SDs were calculated by considering relative proportions. The impact of choice of SDs was evaluated by comparing relative differences between weighted-average disability weights (DW) derived using GBD 2016 worldwide SDs with those derived from Scottish SDs.
 ResultsFor the majority of cancers the most prevalent phase was the controlled phase, which contributed a higher proportion than the combined proportion from the other three phases across all cancers except mesothelioma. Differences in the composition of severity meant that most point-estimates of Scottish severity proportions were out-with the 95% uncertainty intervals. These differences resulted in overestimates of weighted-average DWs based on GBD 2016 worldwide SDs (17 out of 21 cancer types). The largest relative overestimates were for gallbladder and biliary tract cancer, oesophageal cancer and pancreatic cancer (71%, 32% and 31% higher respectively).
 ConclusionThese findings illustrate a systematic bias introduced by using worldwide SDs. Current non-fatal BOD estimates should not be interpreted too precisely when comparing populations when they rely on data inputs from other countries. It is essential to ensure that any estimates are based upon country-specific data as far as possible.

Highlights

  • Burden of Disease (BOD) measures are being used to influence policy decisions because they summarise health loss in an equitable manner

  • The Global Burden of Disease (GBD) study use the same severity distributions (SDs) across countries due to a lack of available data

  • Gallbladder and biliary tract cancer, oesophageal cancer and pancreatic cancer (71%, 32% and 31% higher respectively). These findings illustrate a systematic bias introduced by using worldwide SDs

Read more

Summary

Background

Burden of Disease (BOD) measures are being used to influence policy decisions because they summarise health loss in an equitable manner. An important part of producing non-fatal BOD estimates are severity distributions (SDs). The Global Burden of Disease (GBD) study use the same SDs across countries due to a lack of available data

Conclusion
Methods
Results

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.